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Aims: Metformin is the first line drug for patients diagnosed with type-2 diabetes; however, the impact of different
treatment escalation strategies after metformin failure has thus far not been investigated in a real world situation.
The registry described herein goes some way to clarifying treatment outcomes in such patients.
Methods: DiaRegis is a multicentre registry including 3,810 patients with type-2 diabetes. For the present analysis we
selected patients being treated with metformin monotherapy at baseline (n = 1,373), with the subsequent addition of
incretin-based drugs (Met/Incr; n = 783), sulfonylureas (Met/SU; n = 255), or insulin (n = 220).
Results: After two years 1,110 of the initial 1,373 patients had a complete follow-up (80.8%) and 726 of these were still on
the initial treatment combination (65.4%). After treatment escalation, compared to Met/Incr (n = 421), Met/SU (n = 154)
therapy resulted in a higher HbA1c reduction vs. baseline (−0.6 ± 1.4% vs. −0.5 ± 1.0%; p = 0.039). Insulin (n = 151) resulted
in a stronger reduction in HbA1c (−0.9 ± 2.0% vs. −0.5 ± 1.0%; p = 0.003), and fasting plasma glucose (−24 ± 70 mg/dl
vs. −19 ± 42 mg/dl; p = 0.001), but was associated with increased bodyweight (0.8 ± 9.0 kg vs. −1.5 ± 5.0 kg; p = 0.028).
Hypoglycaemia rates (any with or without help and symptoms) were higher for patients receiving insulin (Odds Ratio
[OR] 8.35; 95% Confidence Interval [CI] 4.84-14.4) and Met/SU (OR 2.70; 95% CI 1.48-4.92) versus Met/Incr. While there
was little difference in event rates between Met/Incr and Met/SU, insulin was associated with higher rates of death,
major cardiac and cerebrovascular events, and microvascular disease.
Conclusions: Taking the results of DiaRegis into consideration it can be concluded that incretin-based treatment
strategies appear to have a favourable balance between glycemic control and treatment emergent adverse effects.
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Metformin is generally the first choice antidiabetic treat-
ment option for patients not achieving adequate blood
glucose control using dietary restrictions alone [1-3].
Sulfonylurea (SU), glitazones, incretin-based treatments,
and insulin are potential subsequent treatment steps ac-
cording to the recent consensus statement of the European
Association for the Study of Diabetes and the American
Diabetes Association [3]. These are considered when
monotherapy with metformin alone does not maintain* Correspondence: gitta@klilu.de
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unless otherwise stated.HbA1c levels at target for approximately 3 months. How-
ever, actual utilisation and performance of these different
strategies with respect to outcomes in real world clinical
practice has not been assessed in detail.
In the present analysis we aimed to 1) describe treat-
ment utilisation and patient characteristics of sulfonyl-
urea (SU) and insulin vs. incretin-based treatment in a
real world setting, 2) identify patients with stable
treatment throughout a two year follow-up, and 3) to
compare blood glucose control, body weight, rates of
hypoglycaemia and incident co-morbidity/vascular events
among the different treatment strategies in those with
stable drug treatment.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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DiaRegis is a prospective, observational, multicentre co-
hort study including 3,810 patients with type-2 diabetes
under the patronage of the foundation “Der herzkranke
Diabetiker”, Germany. It was conducted in accordance
with Good Epidemiology Practice and applicable regula-
tory requirements. The protocol was approved by the
ethics committee of the Landesärztekammer Thüringen
in Jena, Germany on March 4th 2009 and published at
baseline [4]. All patients enrolled into this registry pro-
vided written informed consent and were followed for a
total of 24 months.
Patients
The principal design characteristic of DiaRegis was that
consecutive patients being treated with one or two oral
antidiabetic drugs were enrolled. A second criterion was
that the treating physician had decided to intensify treat-
ment at the baseline visit due to inadequate glycaemic
control. Intensification was achieved by either increasing
the dose of originally prescribed drugs and/or by ex-
changing drugs, or by prescribing additional drugs.
According to protocol, there was no interaction with the
physician in terms of patient selection, nor was the
direction of intensification pre-defined.
Patients without treatment intensification or those on
injectable antidiabetic drug therapy prior to baseline
were not considered eligible. Furthermore, those not
under regular supervision of the treating physician for
the duration of the study, those with type-1 diabetes,
pregnancy, diabetes secondary to malnutrition, infection
or surgery, with maturity onset diabetes of the young,
known cancer or limited life expectancy, acute emergen-
cies, participation in another clinical trial, and patients
with other reasons that would make it difficult for them
to participate and attend the follow-up visits were ex-
cluded from participation.
For the present analysis patients were considered that
were receiving metformin monotherapy prior to baseline,
with treatment being escalated using either incretin-based
drugs, i.e. dipetidyl peptidase-4 inhibitors (DPP-4 I) and
glucagon-like protein-1 agonists (GLP-1 A) (Met/Incr),
sulfonylureas (Met/SU), or insulin. For this purpose,
only drug prescriptions, not doses, were considered.
Drugs were recorded as drug classes and no doses were
documented.
Physicians
Physicians (general practitioners, internists, practi-
tioners, and diabetologists) were selected based on a
conditioned random sampling method. A physician data-
base with approximately 9,350 office based physicians
treating patients with type-2 diabetes were approached
in writing, and physicians with at least 150 patients withtype-2 diabetes under regular medical care and with a
random distribution across all German regions were asked
to participate. This resulted in 313 participating physi-
cians, representing 3.3% of those initially approached.
Documentation
Patient data were entered via a secure website directly
into an electronic database maintained at the Institut für
Herzinfarktforschung, Ludwigshafen, Germany. At this
stage, they were automatically checked for plausibility
and completeness. A detailed over view of the data collec-
tion procedure has been published previously [4]. Data
from the patient questionnaire which each patient was
asked to complete during the baseline visit were trans-
ferred to the clinical research organisation, Winicker
Norimed. The questionnaires were scanned and trans-
ferred to the Institut für Herzinfarktforschung for
evaluation. All data sets were checked for incorrect data
and corrected if applicable; all corrections were docu-
mented. All data sets were submitted for biostatistical
analysis.
Data on co-morbid disease conditions and risk factors
were obtained on an anamnestic basis from the treating
physician, but diagnoses were not objectively verified.
Major adverse cardiac and cerebral events (MACCE)
were defined as any of death, non-lethal myocardial in-
farction (MI), or non-lethal stroke. Microvascular com-
plications included previously unknown retinopathy,
nephropathy, neuropathy, and amputation. Macrovas-
cular complications were defined as new MI, stroke, and
peripheral artery disease (PAD) (including any periph-
eral intervention).
Statistical analysis
Statistical analysis was performed using SAS, version 9.3
(Cary, North Carolina, U.S.A.). The distribution of con-
tinuous variables is described with medians and quartiles.
Categorical parameters are presented as percentages and
absolute numbers. All descriptive statistics are based on
available cases. The adjusted prognostic values of patient
characteristics, laboratory values at baseline, and co-
morbidities on different events during the follow up
period were investigated by using logistic regression ana-
lyses. The resulting odds ratios are presented with corre-
sponding 95% confidence intervals (CI).
Results
Patient characteristics
A total of 3,810 patients were included in DiaRegis, of
which 2,064 received metformin monotherapy at base-
line (Figure 1) and 1,373 of these had an incretin-based
treatment strategy (DPP-4 I or GLP-1 A) (38.0% of pa-
tients; n = 783), or SU (15.7%; n = 324), and an insulin-
Figure 1 Patient population. Legend: Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral antidiabetic drug; BL, baseline;
FU, follow-up.
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treatment options were selected in 33.4% of patients.
Patients selected for Met/Incr treatment (Table 1) had
a lesser age (median 64.0 vs. 67.5 years; p = 0.026), and a
higher bodyweight (median 90.0 vs. 86.0 kg; p = 0.029)
than patients receiving Met/SU. Compared to insulin
patients Met/Incr patients had a lesser diabetes duration
(4.6 vs. 6.6 years; p < 0.001), lower rates of anamnestic
hypoglycaemia (3.6 vs. 23.3%; p < 0.001), and lower blood
glucose values (HbA1c 7.3 vs. 8.1%; fasting plasma glu-
cose, FPG 137 vs. 156 mg/dl; postprandial glucose [PPG]
176 vs. 205 mg/dl). Furthermore, patients receiving insulinTable 1 Patient characteristics at baseline by treatment strate
Met/Incr Met/SU
(n = 783) (n = 32
Age (years) 64.0 (56.7–72.0) 67.5 (58.2–
Female gender (%) 47.6 46.9
Body weight (kg) 90.0 (79.0–103.0) 86.0 (78.0–
Diabetes duration (years) 4.6 (2.1–7.8) 5.2 (2.5–
Blood glucose
HbA1c (%) 7.3 (6.8–7.9) 7.3 (6.8–
FPG (mg/dl) 137 (118–164) 139 (117–
PPG (mg/dl) 176 (147–211) 178 (158–
Anamnestic hypoglycaemia* (%) 3.4 5.2
Concomitant disease (%)
MACCE (%) 9.4 11.2
Macrovascular complication (%) 13.4 13.9
Microvascular complication (%) 14.7 12.4
Legend: Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral an
glucose; PPG, postprandial plasma glucose; MACCE, major cardiac or cerebrovasculahad a higher prevalence of microvascular disease than
patients receiving Met/Incr (22.9 vs. 14.7%; p = 0.002).
For 1,110 out of 1,373 patients with either treatment
strategy, data on the 24 month follow-up were available
(635 Met/Incr, 255 Met/SU, and 220 insulin). Of these,
65.4% retained the initially chosen treatment option,
while 34.6% were switched to another treatment strategy
(Additional file 1: Table S1). Treatment continuity was
66.1% for Met/Incr, 60.4% for Met/SU, and 68.6% for
insulin. The characteristics of patients switched to an
alternative treatment versus those being stable on their
baseline medication are displayed in Table 2.gy (n = 1,373)
p-value
vs. Met/Incr
Insulin ± any OAD p-value
vs. Met/Incr4) (n = 266)
72.8) 0.026 62.6 (54.5–71.5) 0.074
0.83 42.1 0.12
98.5) 0.029 89.0 (78.0–100.0) 0.99
8.6) 0.079 6.6 (3.5–9.9) <0.001
8.1) 0.75 8.1 (7.3–9.5) <0.001
162) 0.91 156 (132–205) <0.001





tidiabetic drug; HbA1c, glycosylated haemoglobin A1c, FPG, fasting plasma
r event; *within 12 months prior to baseline.
Table 2 Patient characteristics at baseline by treatment continuity during 24 month follow-up (n = 1,110)
Met/Incr (n = 635) Met/SU (n = 255) Insulin ± any OAD (n = 220)
Stable Switch Stable Switch Stable Switch
(n = 421; 66.3%) (n = 214; 33.7%) (n = 154; 60.4%) (n = 101; 39.6%) (n = 151; 68.6%) (n = 69; 31.4%)
Age (years) 65.6 (57.7–73.0) 61.6 (55.0–69.2) 68.6 (59.6–73.2) 64.8 (56.8–71.2) 64.0 (54.6–72.9) 58.8 (54.1–65.1)
Female gender (%) 48.7 48.6 51.9 34.7 42.4 44.9
Body weight (kg) 89 (78–101) 91 (80–104) 87 (77–95) 86 (79–103) 90 (80–106) 89 (78–98)
Diabetes duration (years) 4.6 (2.1–7.6) 4.5 (1.7–7.8) 5.3 (2.4–8.6) 5.0 (2.5–8.6) 7.1 (3.6–10.7) 5.6 (2.6–8.3)
Blood glucose
HbA1c (%) 7.2 (6.8–7.7) 7.4 (6.8–8.0) 7.1 (6.7–7.9) 7.3 (6.9–8.2) 8.3 (7.3–9.6) 7.9 (7.1–8.9)
FPG (mg/dl) 134 (116–158) 140 (120–165) 135 (114–158) 133 (117–158) 156 (130–206) 150 (123–182)
PPG (mg/dl) 174 (146–210) 178 (145–210) 177 (158–207) 169 (154–196) 202 (171–239) 198 (165–235)
Anamnestic hypoglycaemia* (%) 2.9 5.1 4.5 7.9 19.2 43.5
Concomitant disease (%)
MACCE (%) 9.3 10.3 11.7 10.0 12.0 4.3
Macrovasc. complication (%) 12.9 16.0 14.3 14.0 20.0 8.7
Microvasc. complication (%) 12.1 18.7 10.3 13.9 23.2 11.6
Legend: Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral antidiabetic drug; HbA1c, glycosylated haemoglobin A1c, FPG, fasting plasma
glucose; PPG, postprandial plasma glucose; MACCE, major cardiac or cerebrovascular event; *within 12 months prior to baseline.
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There was a drop in body weight after 24 months in the
Met/Incr (−1.5 ± 5.0 kg). The change in body weight was not
statistically different compared to Met/Incr in the Met/SU
group (−0.4 ± 4.8 kg; p = 0.17) but there was an increase in
body weight in the insulin group (+0.8 ± 9.0 kg; p = 0.028).
All treatment strategies were associated with reduced
levels of HbA1c and FPG but an increase in posprandial
glucose levels (Table 3). While changes were pronounced
during the first 6 months, they were generally stableTable 3 Changes in efficacy variables from baseline to 24 mont
Met/Incr Met/SU
(n = 421) (n = 154)
HbA1c (%)
BL mean ± SD 7.4 ± 1.1 7.5 ± 1.4
Mean change vs. BL ± SD −0.5 ± 1.0 −0.6 ± 1.4
FPG (mg/dl)
BL mean ± SD 142 ± 41 143 ± 43
Mean change vs. BL ± SD −19 ± 42 −15 ± 41
PPG (mg/dl)
BL mean ± SD 201 ± 243 189 ± 52
Mean change vs. BL ± SD 27 ± 463 60 ± 330
Body weight (kg)
BL mean ± SD 91.2 ± 17.9 88.1 ± 14.8
Mean change vs. BL ± SD −1.5 ± 5.0 −0.4 ± 4.8
Legend: BL, baseline; Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea;
fasting plasma glucose; PPG, postprandial plasma glucose; SD, standard deviation. *
diabetes duration, heart failure, coronary artery disease, HbA1c, FPG, and PPG.thereafter for Met/Incr- and Met/SU-treated patients, but
levels increased slightly for patients using insulin. The only
significant difference between Met/Incr and the Met/SU
group was seen for mean HbA1c which was less reduced
in the Met/Inr group (−0.5 ± 1.0%; p = 0.039). Compared
to the insulin group, patients with Met/Incr had a lesser
reduction of HbA1c (−0.5 ± 1.0% vs −0.9 ± 2.0%; p = 0.003)
and fasting blood glucose (−19 ± 42 mg/dl vs. -24 ±
70 mg/dl; p = 0.001) while differences in mean PPG
changes were not significant (27 ± 463 mg/dl vs. 90 ±
535 mg/dl; p = 0.066).hs for those remaining on the chosen treatment (n = 726)
p-value*
vs. Met/Incr
Insulin ± any OAD p-value*
vs. Met/Incr(n = 151)
8.6 ± 1.7
0.039 −0.9 ± 2.0 0.003
173 ± 66
0.34 −24 ± 70 0.001
224 ± 130
0.61 90 ± 535 0.066
93.7 ± 19.6
0.17 0.8 ± 9.0 0.028
OAD, oral antidiabetic drug; HbA1c, glycosylated haemoglobin A1c, FPG,
Adjusted for differences in baseline characteristics: age, sex, body weight,
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Hypoglycaemia was frequently asymptomatic or at a
level at which there was no requirement for help
(Table 4). Incidence of any hypoglycaemia was lowest in
patients receiving to Met/Incr (6.5%) and it was substan-
tially higher in those receiving Met/SU (15.4%; OR 2.70;
95% CI 1.48–4.92) or insulin (37.1%; OR 8.35; 95% CI
4.84–14.4). Even greater elevations over Met/Incr were
seen for symptomatic hypoglycaemia without the need for
help (insulin OR 11.45; 95% CI 5.90–22.2 and Met/SU OR
3.13; 95% CI 1.46–6.99).
Death, MACCE and macrovascular complications
were lowest in patients receiving Met/Incr while micro-
vascular complications were lowest in Met/SU patients.
Albeit nominally different there was no statistically sig-
nificant different in event rates compared to Met/Incr in
the Met/SU group. On the other hand death (OR 4.65;
95% CI 1.68–12.9), MACCE (OR 3.08; 95% CI 1.27–
7.48), and microvascular complications (OR 3.84; 95%
CI 2.13–6.90) were substantially increased in those re-
ceiving insulin vs. those receiving Met/Incr.Discussion
Following a diagnosis of type-2 diabetes, almost all
patients are initially treated with metformin. Within a
few months or years, however, the majority require the
addition of another treatment strategy. For a number of
decades, SU and insulin have been considered to be the
second line treatment options, although they are associ-
ated with a progressive decline in beta-cell function.
Furthermore, both are associated with a high prevalence
of hypoglycaemia, weight gain, and other side effects
related to individual agents [5,6]. They have also beenTable 4 Hypoglycaemia rates and events from baseline to 24
Met/Incr Met/SU
(n = 421) (n = 154)
Hypoglycaemia with need for help 0.8 0.6
Symptomatic hypoglycaemia
without need for help
4.3 10.3
Asymptomatic hypoglycaemia
without need for help
3.6 10.1




Macrovascular complications 1.7 2.7
Microvascular complications† 7.7 6.0
Legend: Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral an
those with any neuropathy and any retinopathy at baseline. *Adjusted for differenc
artery disease.shown to be linked with an increased incidence of
cardiovascular events [6,7].
Incretin-based treatment strategies on the other hand,
have been shown to preserve beta-cell function, support
weight neutrality or even weight loss, and have a low
intrinsic risk of hypoglycaemia. In addition gliptins have
been shown to reverse pro-angiogenic cells dysfunction
associated with type-2-diabetes in vitro and to improve
inducible angiogenesis by circulating cells in vivo [8],
normalize retinal capillary flow and improves central
hemodynamics [9], and restore vascular mitochondrial
adaptation to exercise in a diabetic rodent model and
may augment the impact of exercise on the vasculature
[10]. Most importantly, clinical trials such as EXAMINE
and SAVOR TIMI 53 have shown that alogliptin as well
as saxagliptin are non-inferior to a placebo in patients at
high cardiovascular risk, even after acute coronary syn-
dromes [11,12]. A recent pooled analysis of 20 clinical
trials confirmed the safety for the cardiovascular system
[13]. A potential limitation of the good risk profile of
gliptins are the finding of an increased risk for heart fail-
ure, particularly in patients with elevated natriuretic
peptides, previous heart failure or chronic kidney disease
[11]. Despite their remarkably increased use, health
authorities in different countries, including Germany, re-
gard incretin-based treatment strategies to be second to
those based on SU or insulin. This has prompted us to
take a closer look at real world treatment patterns, treat-
ment durability, glucose control, and other outcomes in
clinical practice.
SU vs. incretin-based treatment strategies on top of
metformin
Using a large dataset of type-2 diabetic patients in
Germany we were able to assess real world treatmentmonths for those remaining on the chosen treatment (%)
OR (95% CI)
*vs. Met/Incr
Insulin ± any OAD OR (95% CI)*
vs. Met/Incr(n = 151)
1.32 (0.12–15.0) 1.4 2.42 (0.30–19.3)
3.13 (1.46–6.69) 31.3 11.45 (5.90–22.2)
2.74 (1.33–8.70) 22.9 8.33 (4.33–16.0)
2.70 (1.48–4.92) 37.1 8.35 (4.84–14.4)
2.11 (0.65–6.87) 7.3 4.65 (1.68–12.9)
2.31 (0.93–5.78) 8.0 3.08 (1.27–7.48)
1.53 (0.43–5.44) 2.1 1.04 (0.25–4.42)
0.87 (0.40–1.90) 20.7 3.84 (2.13–6.90)
tidiabetic drug; MACCE, major cardiac or cerebrovascular event. †Excluding
es in baseline characteristics: age, sex, diabetes duration, and coronary
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adding SU in patients with higher age and low bodyweight
was identified. Met/SU treatment resulted in adequate
glucose control and was continued in approximately 60%
of patients over the follow-up period, which was only
slightly poorer than with the other treatment strategies.
There was no issue with regard to weight gain, but the
rates of hypoglycaemia (without the need for help) were
increased with an OR of around 3. Furthermore, although
nominally increased, the rate of cardiovascular events was
not significantly different from those experienced by
patients being treated with incretin-based therapies.
These results are principally in agreement with a recent
meta-analysis regarding the effects of DPP-4 inhibitors
[14], which demonstrated a slight advantage of SU over
DPP-4 inhibitors in reducing HbA1c (weighted mean dif-
ference 0.07%). Furthermore, the meta-analysis identified
a mean difference in body weight of −1.92 kg in favour of
DPP-4 inhibitors, which was larger than the −1.4 kg we
observed; however, the difference between the two treat-
ment strategies in the present study was not statistically
significant. In line with our own results, most trials
comparing a DPP-4 inhibitor with SU, in combination
with metformin, demonstrate a slightly higher risk of
hypoglycaemia in the latter group [15-18]. Within this
context, different generations of SU have to be consid-
ered, although we did not capture them individually.
Second generation glibenclamide and glipizide are ex-
tensively used and are known to have a quite significant
risk of hypoglycaemia [19,20]. Episodes with these
agents may be persistent because of their prolonged
half-life and binding to the SU receptor, causing it to be
less sensitive to glucose levels [21,22]. Insulin is se-
creted in turn, increasing the risk of hypoglycaemia
[23]. On the other hand, the third generation SUs glicla-
zide and glimepiride have different receptor binding prop-
erties, reducing the risk of hypoglycaemia and are
potentially more favourable treatment alternatives [24,25].
Information on the risk of cardiovascular events with
incretin-based treatment strategies and SU are conflicting
[26,27]. Recent analyses have suggested an increased risk
of death due to cardiovascular causes, with an OR between
1.92 and 2.93 in patients receiving SU therapy compared
to other treatment options [26]. Furthermore, in a review
of 115 randomised, controlled trials, SU was associated
with an increased mortality (OR 1.22), stroke (OR 1.28),
and MACCE (OR 1.85, if only the comparison with DPP-4
inhibitors was considered) [27]. On the other hand, the
recent analysis by Karagiannis [14] demonstrated no differ-
ence in all-cause mortality between DPP-4 inhibitors and
those receiving SU. Against this background, our finding of
a nominally increased event risk with no statistical signifi-
cance after multivariable adjustment appears reasonable,
but does not add clarity to the ongoing dispute. Within thiscontext, the limitations of an observational study that has a
less than perfect degree of follow-up (80% in the case of
DiaRegis) has to be kept in mind, given that a loss to
follow-up can potentially also mean patient death.
Insulin vs. incretin-based treatment in combination with
metformin
In the present registry, insulin was predominantly used
in patients with long-standing diabetes, higher blood
glucose values, and a higher prevalence of microvascular
disease, indicating a more advanced disease stage.
Hypoglycaemia was more frequent in patients on a later
insulin treatment giving rise to the speculation that these
may have been patients with more advance disease, a high
variability in blood glucose and a higher cardiovascular
disease burden – conditions that have been associated
with a higher risk of hypoglycaemia. Surprisingly, even
hypoglycaemia on prior oral therapy did not prevent
physicians from introducing an insulin-based treatment
strategy. Insulin use was continued in 68.6% of patients
throughout the 2 year follow-up. While insulin use was
associated with a strong reduction in HbA1c and FPG,
albeit from a higher baseline value, it was associated
with increases in body weight and rate of hypoglycaemia.
By the end of the two year follow-up period, 7.3% of
patients had died (OR 4.65), 8.0% had experienced a
MACCE (OR 3.08), and 20.7% any microvascular com-
plication (OR 3.94), which was significantly higher than
for the patients that had received an incretin-based
treatment strategy in combination with metformin.
A number of considerations have to be taken into ac-
count when discussing these observations. Patients being
considered for insulin treatment are usually those with
an advanced stage of diabetes (median duration 6.6 vs.
4.6 years in DiaRegis) and higher blood glucose levels
(HbA1c 8.1 vs. 7.3%), with corresponding changes in
FPG and PPG. This is because insulin is known to effect-
ively control hyperglycaemia and glucotoxicity, and to
reduce lipotoxicity and inflammation [28]. This could
potentially favourably influence the preservation of beta-
cell function, but has to be prescribed at an early stage
after diagnosis [29], where adverse cardiovascular effects
are comparable to those experienced with other treat-
ment options. Clinical practice surveys such as DiaRegis,
however, reconfirm that insulin is usually initiated in
those failing on a number of previously attempted treat-
ment options and in patients with a high degree of
co-morbidity.
Hypoglycaemia is one of the most critical factors in the
management of type-2 diabetes. Insulin often causes sig-
nificant hypoglycaemia in addition to weight gain, and clin-
ical trials such as ACCORD, ADVANCE, and VADT have
suggested that mortality rates may be increased in patients
with episodes of severe hypoglycaemia [30-32]. Against this
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patients treated with insulin in comparison to those ad-
ministered incretin-based therapies in the DiaRegis study
are noteworthy, with an OR of 11.45 for symptomatic
hypoglycaemia and 8.33 for asymptomatic hypoglycaemia.
Rates of severe hypoglycaemia necessitating help were
also increased (OR 2.42) but did not reach statistical
significance.
Whether or not the previously discussed changes dir-
ectly result in increased morbidity and mortality cannot
be derived from the present analysis. It is evident, how-
ever, that patients selected for insulin treatment at base-
line had a substantially increased death rate at 2 years
(7.3 vs. 1.7%; OR 4.65), a higher rate of MACCE (8.0 vs.
2.6%; OR 3.08), and a greater incidence of microvascular
morbidity (20.7 vs. 7.7%; OR 3.84). Randomised con-
trolled studies comparing incretin-based treatments and
insulin are usually too short to assess differences in out-
comes; therefore it is clear that future studies should
address this. In the recent DURATION-2 trial, once-
weekly administration of the GLP-1 agonist exenatide
was compared to insulin glargine for a total duration of
26 weeks [33]. The trial demonstrated that exenatide is a
viable and more convenient alternative in those with a
risk of hypoglycaemia and weight gain, but did not show
differences in survival. Retrospective analyses of the
United Kingdom General Practitioners research data-
base, however, confirmed our observation that insulin
treated patients had an increased risk of death (OR 2.2),
MACCE (OR 1.7), and microvascular complications
combined (OR 1.4) [6]. This difference may relate to the
higher baseline risk noted for patients chosen for insulin
over incretin-based treatments in DiaRegis.
Limitations
Despite the real world nature of DiaRegis and the direct
impact for clinical practice, there are a number of limita-
tions that are worth mentioning: 1) We documented
drug classes (yes/no) rather than specific drugs in a
given class and no information on drug doses prescribed.
This was done in an effort to maintain a pragmatic case
report form with variables limited to the ones needed.
Furthermore the recording of drugs and doses would
have resulted in groups that would have been consider-
ably smaller with no added value given the overall sam-
ple size pursued. 2) Group assignment was made based
on the treatment decision made by the treating phys-
ician. On the one hand this is a limitation of the present
analysis because it does not allow random group assign-
ment and thus a comparability of groups that is required
to directly compare outcomes. On the other hand this
approach allows to record treatment decisions and the
underlying patient characteristics being associated to
these decisions. To overcome this limitation we adjustedthe outcome variables for baseline characteristics, ac-
knowledging that this might not be able to balance the
groups completely. For further more elaborate analyses
such as propensity score matching group size was not
large enough. Finally we had a loss of about 20% of
patients during the 2-year follow-up which results in
some uncertainty as to the findings of this registry.
Conclusions
Taking the results of DiaRegis into consideration, it can
be concluded that incretin-based treatment strategies
appear to have a favourable balance between glycemic
control and treatment emergent adverse effects. in type-
2 diabetics failing on metformin. The establishment of
this registry has gone some way to assessing the out-
comes of treatment strategies for such patients in a real
world clinical setting.
Additional file
Additional file 1: TableS1. Pharmacotherapy post baseline and after 24
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